Jean Boyer

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

Cornelia L. Trimble, Matthew P. Morrow, Kimberly A. Kraynyak et al. · The Lancet · 2015 · 689 citations

Immunology, Human Papillomavirus 16, Cancer-associated Virus +17

Gene inoculation generates immune responses against human immunodeficiency virus type 1.

B Wang, Kenneth E. Ugen, Vasantha Srikantan et al. · Proceedings of the National Academy of Sciences · 1993 · 653 citations · Full text

Immunology, Gene Inoculation, Immune System +16

First Human Trial of a DNA-Based Vaccine for Treatment of Human Immunodeficiency Virus Type 1 Infection: Safety and Host Response

Rob Roy MacGregor, Jean Boyer, Kenneth E. Ugen et al. · The Journal of Infectious Diseases · 1998 · 638 citations · Full text

Immunogenicity of a DNA vaccine candidate for COVID-19

Trevor R.F. Smith, Ami Patel, Stephanie Ramos et al. · Nature Communications · 2020 · 635 citations · Full text

Gene transfer in humans using a conditionally replicating lentiviral vector

Bruce L. Levine, Laurent Humeau, Jean Boyer et al. · Proceedings of the National Academy of Sciences · 2006 · 501 citations · Full text

Engineering, Genetics, Immunology +16